Auxilium Pharma (AUXL) Boosts FY12 Revs Outlook; Sees Lower Net Losses
Tweet
Share
E-mailGet Alerts AUXL Hot Sheet
Price: $36.47 --0%
Financial Fact:
Cost of goods sold: 25.71M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of goods sold: 25.71M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) is raising its full year 2012 revenue guidance to a range of $293 to $315 million and is reducing its guidance for net loss to a range of $5 to $10 million. The Street sees revs of $299.2 million.
The Company will be holding a conference call today, May 21, 2012, at 10:00 am ET to discuss the agreement for the Testim® U.S. co-promotion with GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (LSE: GSK).
The Company will be holding a conference call today, May 21, 2012, at 10:00 am ET to discuss the agreement for the Testim® U.S. co-promotion with GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (LSE: GSK).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
